MEA112997 Open-label Long Term Extension Safety Study of Mepolizumab in Asthmatic Subjects
Status:
Completed
Trial end date:
2017-05-31
Target enrollment:
Participant gender:
Summary
This is a multi-centre, open-label long term safety study of 100 milligrams (mg) mepolizumab
administered subcutaneously (SC) in addition to standard of care in subjects who participated
in the MEA112997 study. At each clinic visit, adverse events will be assessed and
exacerbations will also be reviewed.